{
    "nctId": "NCT01597193",
    "briefTitle": "Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer",
    "officialTitle": "A PHASE 1 OPEN-LABEL, DOSE ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE (FORMERLY MDV3100) IN PATIENTS WITH INCURABLE BREAST CANCER",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 101,
    "primaryOutcomeMeasure": "Dose-Escalation Phase: Percentage of Participants With Dose-limiting Toxicity (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed breast cancer with accompanying pathology report;\n* Submit unstained representative tumor specimen, either as a paraffin block (preferred) or \u2265 10 unstained slides\n* Received at least 2 lines of systemic therapy in the advanced setting (for enzalutamide alone arm only);\n* Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;\n* Estimated life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment;\n* Pregnant or lactating;\n* Known or suspected brain metastasis or leptomeningeal disease;\n* History of another malignancy within the previous 5 years other than curatively treated in situ carcinomas;\n* For patients who are enrolled to receive enzalutamide plus anastrozole or exemestane or fulvestrant must not have received tamoxifen or any medication known to be a potent CYP3A4 inducer or inhibitor.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}